Christopher U. Missling net worth and biography

Christopher Missling Biography and Net Worth

Dr. Missling, President and CEO of Anavex, has over 20 years of healthcare industry experience within large pharmaceutical companies, the biotech industry and investment banking. Prior to joining Anavex®, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sanofi), Dr. Missling worked as head of financial planning on all aspects of financial strategy and M&A. His career experience also includes working as an investment banker in the healthcare practice at Deutsche Bank, serving pharmaceutical, biotech, and diagnostic companies, as well as serving as the head of healthcare investment banking at Brimberg & Co. in New York. Dr. Missling has an MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management.

What is Christopher U. Missling's net worth?: The estimated net worth of Christopher U. Missling is at least $11.78 million as of March 28th, 2024. Dr. Missling owns 1,250,210 shares of Anavex Life Sciences stock worth more than $11,776,978 as of April 28th. This net worth approximation does not reflect any other assets that Dr. Missling may own. Additionally, Dr. Missling receives an annual salary of $828,250.00 as CEO at Anavex Life Sciences. Learn More about Christopher U. Missling's net worth.
How old is Christopher U. Missling?: Dr. Missling is currently 58 years old. There are 1 older executives and no younger executives at Anavex Life Sciences. Learn More on Christopher U. Missling's age.
What is Christopher U. Missling's salary?: As the CEO of Anavex Life Sciences Corp., Dr. Missling earns $828,250.00 per year. Learn More on Christopher U. Missling's salary.
How do I contact Christopher U. Missling?: The corporate mailing address for Dr. Missling and other Anavex Life Sciences executives is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. Anavex Life Sciences can also be reached via phone at (844) 689-3939 and via email at ir@anavex.com. Learn More on Christopher U. Missling's contact information.
Has Christopher U. Missling been buying or selling shares of Anavex Life Sciences?: Christopher U. Missling has not been actively trading shares of Anavex Life Sciences during the past quarter. Most recently, Christopher U. Missling sold 73,380 shares of the business's stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $5.11, for a transaction totalling $374,971.80. Following the completion of the sale, the chief executive officer now directly owns 1,250,210 shares of the company's stock, valued at $6,388,573.10. Learn More on Christopher U. Missling's trading history.
Who are Anavex Life Sciences' active insiders?: Anavex Life Sciences' insider roster includes Sandra Boenisch (Treasurer), Peter Donhauser (Director), Elliot Favus (Director), Elliot Favus (Director), Christopher Missling (CEO), and Steffen Thomas (Director). Learn More on Anavex Life Sciences' active insiders.
Are insiders buying or selling shares of Anavex Life Sciences?: In the last twelve months, Anavex Life Sciences insiders bought shares 2 times. They purchased a total of 7,835 shares worth more than $32,919.40. The most recent insider tranaction occured on June, 14th when Director Peter D.O. Donhauser bought 2,835 shares worth more than $10,319.40. Insiders at Anavex Life Sciences own 11.0% of the company. Learn More about insider trades at Anavex Life Sciences.
Information on this page was last updated on 6/14/2024.

Christopher U. Missling Insider Trading History at Anavex Life Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/28/2024	Sell	73,380	$5.11	$374,971.80	1,250,210
6/28/2023	Sell	268,000	$7.98	$2,138,640.00	1,018,210
3/7/2018	Buy	1,360	$2.92	$3,971.20
3/5/2018	Buy	1,500	$2.63	$3,945.00	1,015,400
3/2/2018	Buy	1,650	$2.41	$3,976.50	1,013,900
10/24/2017	Buy	375	$4.92	$1,845.00	1,011,875
10/19/2017	Buy	375	$4.49	$1,683.75	1,011,500
10/17/2017	Buy	375	$4.27	$1,601.25
10/13/2017	Buy	750	$4.22	$3,165.00
10/5/2017	Buy	375	$4.30	$1,612.50
10/2/2017	Buy	375	$4.20	$1,575.00	1,009,625
9/28/2017	Buy	375	$4.21	$1,578.75	1,009,250
9/26/2017	Buy	375	$3.88	$1,455.00	1,008,875
9/20/2017	Buy	375	$4.23	$1,586.25	1,008,500
9/18/2017	Buy	375	$4.40	$1,650.00	1,008,125
9/14/2017	Buy	375	$4.58	$1,717.50	1,007,750
9/11/2017	Buy	375	$4.81	$1,803.75	1,007,375
9/7/2017	Buy	375	$4.76	$1,785.00	1,007,000
9/5/2017	Buy	375	$4.90	$1,837.50	1,006,625
8/31/2017	Buy	375	$4.48	$1,680.00	1,006,250
8/28/2017	Buy	375	$4.44	$1,665.00	1,005,875
8/24/2017	Buy	375	$4.54	$1,702.50	1,005,500
8/21/2017	Buy	375	$4.07	$1,526.25	1,005,125
8/18/2017	Buy	375	$3.81	$1,428.75	1,004,750
8/14/2017	Buy	375	$3.70	$1,387.50	1,004,375
8/11/2017	Buy	750	$3.55	$2,662.50	1,004,000
7/14/2015	Buy	1,000	$0.52	$520.00
7/13/2015	Buy	1,000	$0.53	$530.00
7/7/2015	Buy	2,000	$0.49	$980.00
7/1/2015	Buy	2,000	$0.45	$900.00
6/23/2015	Buy	1,000	$0.47	$470.00
6/22/2015	Buy	1,000	$0.42	$420.00
6/16/2015	Buy	1,000	$0.44	$440.00
6/15/2015	Buy	1,000	$0.43	$430.00
6/10/2015	Buy	1,000	$0.36	$360.00
6/8/2015	Buy	1,000	$0.35	$350.00
6/4/2015	Buy	1,000	$0.37	$370.00

See Full Table

Christopher U. Missling Buying and Selling Activity at Anavex Life Sciences

Anavex Life Sciences Company Overview

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Today's Range

Now: $9.42

$9.31

$9.66

50 Day Range

MA: $8.79

$7.60

$9.93

2 Week Range

Now: $9.42

$3.41

$14.44

Volume

308,122 shs

Average Volume

1,233,520 shs

Market Capitalization

$801.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8

Christopher Missling Biography and Net Worth

What is Christopher U. Missling's net worth?

How old is Christopher U. Missling?

What is Christopher U. Missling's salary?

How do I contact Christopher U. Missling?

Has Christopher U. Missling been buying or selling shares of Anavex Life Sciences?

Who are Anavex Life Sciences' active insiders?

Are insiders buying or selling shares of Anavex Life Sciences?